Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program
Study context
- Population
- Elderly and obese patients (60–84 years, BMI >28 kg/m²) with ≥1 of hypertension, CVD or CKD, without diabetes or heart failure (HF)138 randomised at present
- Participants
- 204 elderly
- Planned comparison
- Empagliflozin vs placebo
- Primary endpoint
- Empire Prevent Cardiac: peak oxygen consumption and LV mass; Empire Prevent Metabolic: changes in epicardial adipose tissue and estimated extracellular volume
- Follow-up
- 180 days
Methodological detailsinvestigator-initiated, double-blind, placebo-controlled, 1:1 randomisation
- Investigator-initiated
- Double-blind
- Placebo-controlled
- 1:1 randomisation
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program. Am Heart J. Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →